BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Nanosystems for Targeted Therapy and Molecular Immunosensing of Ov
 arian Cancer (seminar postponed from June 17\, 2013)
DTSTART:20130701T140000
DTEND:20130701T150000
DTSTAMP:20260604T231006Z
UID:c0e0b9e1b202848cc09319e1ac1c4c7b63887d4dfd785339ab237512
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Yadollah Omidi\, Ovarian Cancer Research Center\, Perelm
 an School of Medicine\, University of Pennsylvania\, Philadelphia\, PA (US
 A)\nBio: Dr. Omidi is Associate Professor of Pharmaceutical Nanobiotechnol
 ogy and Drug Targeting. He holds a pharmacy doctorate degree (1991) from T
 abriz University of Medical Sciences (TUOMS) and a Ph.D. degree (2003) fro
 m Cardiff University. He has postdoctoral research associate experience (2
 002-2004) working on gene-based nanomedicines and toxicogenomics in the Ce
 nter for Genome-based Therapeutics at Welsh School of Pharmacy\, Cardiff U
 niversity. From 2004 till 2011\, he has worked as associate professor at T
 UOMS Faculty of Pharmacy and also founded the Research Center for Pharmace
 utical Nanotechnology (RCPN)\, ranked as the number one center of excellen
 ce in Iran (2008-2011)\, and the School of Advanced Biomedical Sciences. S
 ince 2008\, Dr. Omidi is a member of the National Academy of Medical Scien
 ces of Iran and is recipient of the Razi Festival Award for advancing biom
 edical research. In July 2011\, he joined the Ovarian Cancer Research Cent
 er (OCRC) at University of Pennsylvania as a Visiting Associate Professor 
 to develop/advance translational nanomedicines focusing on multifunctional
  nanomedicines and theranostics for simultaneous diagnosis and therapy of 
 cancer. Dr. Omidi has published over 80 papers and more than 10 book chapt
 ers.\nMost of ovarian cancer (OC) patients are diagnosed in the late stage
  of the disease when it has already disseminated beyond the ovaries\, whil
 e the currently used treatment modalities often fail to effectively cure t
 he disease. Thus\, OC patients need to be diagnosed at the early stage and
  efficiently treated with targeted therapies using synthetic lethality. He
 re\, we present engineered nanosystems (NSs) for targeted therapy and mole
 cular immunosensing of OC. For targeted therapy\, we engineered biodegrada
 ble nanoparticles (NPs) of poly(lactic-co-glycolic acid) containing cytoto
 xic agents or drugs inhibiting OC cells transporters involved in pH dysreg
 ulation to simultaneously target key molecular elements of OC within tumor
  microenvironment. The NPs were decorated with polyethylene glycol and ant
 i-tumor endothelial marker 1 (TEM1) antibody (Ab)/scFv. These NSs (220 
 nm) showed sustained-release profile and actively inhibited TEM-1 expressi
 ng MS-1 endothelial cells and OVCAR-5 cells. For molecular sensing\, we ca
 pitalized on preparation of improved immunosensor to sense CA125 expressed
  by OC cells and found in OC patients serum. To amplify the sensing signal
 s\, surface of the electrodes were decorated with NPs (20 nm) that were ar
 med with anti-CA125 Ab using silica coated gold NPs or CdSe quantum dots. 
 The engineered immunosensors were successfully tested using EIS and CV met
 hods showing high precision. These NSs may be used for successful detectio
 n and effective therapy of OC as well as other solid tumors.
LOCATION:SV 1717A http://plan.epfl.ch/?reset_session&room=sv1717a
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR